Abstract
We previously showed that viable Mycobacterium tuberculosis (Mtb) bacilli contain distinct ligands that activate cells via the mammalian Toll-like receptor (TLR) proteins TLR2 and TLR4. We now demonstrate that expression of a dominant negative TLR2 or TLR4 proteins in RAW 264.7 macrophages partially blocked Mtb-induced NF-kappa B activation. Coexpression of both dominant negative proteins blocked virtually all Mtb-induced NF-kappa B activation. The role of the TLR4 coreceptor MD-2 was also examined. Unlike LPS, Mtb-induced macrophage activation was not augmented by overexpression of ectopic MD-2. Moreover, cells expressing an LPS-unresponsive MD-2 mutant responded normally to Mtb. We also observed that the lipid A-like antagonist E5531 specifically inhibited TLR4-dependent Mtb-induced cellular responses. E5531 could substantially block LPS- and Mtb-induced TNF-alpha production in both RAW 264.7 cells and primary human alveolar macrophages (AM phi). E5531 inhibited Mtb-induced AM phi apoptosis in vitro, an effect that was a consequence of the inhibition of TNF-alpha production by E5531. In contrast, E5531 did not inhibit Mtb-induced NO production in RAW 264.7 cells and AM phi. Mtb-stimulated peritoneal macrophages from TLR2- and TLR4-deficient animals produced similar amounts of NO compared with control animals, demonstrating that these TLR proteins are not required for Mtb-induced NO production. Lastly, we demonstrated that a dominant negative MyD88 mutant could block Mtb-induced activation of the TNF-alpha promoter, but not the inducible NO synthase promoter, in murine macrophages. Together, these data suggest that Mtb-induced TNF-alpha production is largely dependent on TLR signaling. In contrast, Mtb-induced NO production may be either TLR independent or mediated by TLR proteins in a MyD88-independent manner.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antigens, Surface / biosynthesis
-
Antigens, Surface / physiology
-
Antitubercular Agents / pharmacology
-
Apoptosis / drug effects
-
CHO Cells
-
Cell Line
-
Cricetinae
-
Cricetulus
-
Drosophila Proteins*
-
Female
-
Gene Expression Regulation
-
Lipid A / analogs & derivatives
-
Lipid A / pharmacology*
-
Lipopolysaccharides / antagonists & inhibitors
-
Lipopolysaccharides / pharmacology
-
Lymphocyte Antigen 96
-
Macrophages / drug effects
-
Macrophages / metabolism
-
Macrophages / microbiology*
-
Macrophages, Alveolar / cytology
-
Macrophages, Alveolar / drug effects
-
Macrophages, Alveolar / microbiology
-
Membrane Glycoproteins / antagonists & inhibitors*
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / pharmacology
-
Membrane Glycoproteins / physiology
-
Mesocricetus
-
Mice
-
Mice, Inbred C3H
-
Mutation
-
Mycobacterium tuberculosis / drug effects
-
Mycobacterium tuberculosis / physiology*
-
NF-kappa B / antagonists & inhibitors
-
NF-kappa B / metabolism
-
Nitric Oxide / biosynthesis
-
Nitric Oxide Synthase / genetics
-
Nitric Oxide Synthase Type II
-
Promoter Regions, Genetic / immunology
-
Receptors, Cell Surface / antagonists & inhibitors*
-
Receptors, Cell Surface / genetics
-
Receptors, Cell Surface / physiology
-
Recombinant Proteins / genetics
-
Recombinant Proteins / pharmacology
-
Toll-Like Receptor 2
-
Toll-Like Receptor 4
-
Toll-Like Receptors
-
Tuberculosis / mortality
-
Tuberculosis / prevention & control
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / biosynthesis
-
Tumor Necrosis Factor-alpha / genetics
Substances
-
Antigens, Surface
-
Antitubercular Agents
-
Drosophila Proteins
-
Lipid A
-
Lipopolysaccharides
-
Lymphocyte Antigen 96
-
Membrane Glycoproteins
-
NF-kappa B
-
Receptors, Cell Surface
-
Recombinant Proteins
-
Toll-Like Receptor 2
-
Toll-Like Receptor 4
-
Toll-Like Receptors
-
Tumor Necrosis Factor-alpha
-
Nitric Oxide
-
E 5531
-
Nitric Oxide Synthase
-
Nitric Oxide Synthase Type II
-
Nos2 protein, mouse